Do analysts recommend HEPA or SNYR?

Synergy CHC has a consensus price target of $6.25, suggesting a potential upside of 3,713.30%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts plainly believe Synergy CHC is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Synergy CHC 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer HEPA or GRI?

GRI Bio has a consensus price target of $32.00, suggesting a potential upside of 1,964.52%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, HEPA or GRI?

GRI Bio is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A GRI Bio N/A N/A -$11.96M -$74.16 N/A

Is HEPA or GRI more profitable?

GRI Bio's return on equity of -199.52% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% GRI Bio N/A -199.52% -143.23%

Does the media favor HEPA or GRI?

In the previous week, Hepion Pharmaceuticals and Hepion Pharmaceuticals both had 1 articles in the media. Hepion Pharmaceuticals' average media sentiment score of 0.67 beat GRI Bio's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hepion Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CASI or HEPA?

CASI Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend GOVX or HEPA?

GeoVax Labs currently has a consensus price target of $150.00, indicating a potential upside of 20,698.67%. Given GeoVax Labs' stronger consensus rating and higher possible upside, research analysts plainly believe GeoVax Labs is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GOVX or HEPA more profitable?

GeoVax Labs' return on equity of -743.64% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% Hepion Pharmaceuticals N/A -812.56% -207.31%

Does the media prefer GOVX or HEPA?

In the previous week, GeoVax Labs had 7 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 8 mentions for GeoVax Labs and 1 mentions for Hepion Pharmaceuticals. GeoVax Labs' average media sentiment score of 0.88 beat Hepion Pharmaceuticals' score of 0.67 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hepion Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate HEPA or DCOY?

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 638.92%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, HEPA or DCOY?

Decoy Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is HEPA or DCOY more profitable?

Decoy Therapeutics' return on equity of -395.42% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% Decoy Therapeutics N/A -395.42% -193.30%

Does the media favor HEPA or DCOY?

In the previous week, Hepion Pharmaceuticals and Hepion Pharmaceuticals both had 1 articles in the media. Hepion Pharmaceuticals' average media sentiment score of 0.67 beat Decoy Therapeutics' score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hepion Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Decoy Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Hepion Pharmaceuticals (HEPA) Competitors

$0.06 -0.01 (-14.16%)

As of 08/6/2026 01:31 PM Eastern

Compare

HEPA vs. SNYR, GRI, CASI, GOVX, and DCOY

Should you buy Hepion Pharmaceuticals stock or one of its competitors? MarketBeat compares Hepion Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hepion Pharmaceuticals include Synergy CHC (SNYR), GRI Bio (GRI), CASI Pharmaceuticals (CASI), GeoVax Labs (GOVX), and Decoy Therapeutics (DCOY).

How does Hepion Pharmaceuticals compare to Synergy CHC?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Synergy CHC (NASDAQ:SNYR) are related small-cap companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Synergy CHC has a consensus price target of $6.25, suggesting a potential upside of 3,713.30%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts plainly believe Synergy CHC is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Comparatively, 32.9% of Synergy CHC shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Hepion Pharmaceuticals had 1 more articles in the media than Synergy CHC. MarketBeat recorded 1 mentions for Hepion Pharmaceuticals and 0 mentions for Synergy CHC. Hepion Pharmaceuticals' average media sentiment score of 0.67 beat Synergy CHC's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hepion Pharmaceuticals	Positive
Synergy CHC	Neutral

Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market.

Synergy CHC has higher revenue and earnings than Hepion Pharmaceuticals. Synergy CHC is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
Synergy CHC	$30.38M	0.08	-$12.34M	-$1.40	N/A

Hepion Pharmaceuticals has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Synergy CHC	-60.02%	N/A	-30.30%

Summary

Synergy CHC beats Hepion Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to GRI Bio?

Hepion Pharmaceuticals (NASDAQ:HEPA) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Comparatively, 8.7% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

GRI Bio has a consensus price target of $32.00, suggesting a potential upside of 1,964.52%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Hepion Pharmaceuticals and Hepion Pharmaceuticals both had 1 articles in the media. Hepion Pharmaceuticals' average media sentiment score of 0.67 beat GRI Bio's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hepion Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, GRI Bio has a beta of -1.21, suggesting that its share price is 221% less volatile than the broader market.

GRI Bio's return on equity of -199.52% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
GRI Bio	N/A	-199.52%	-143.23%

GRI Bio is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A

Summary

GRI Bio beats Hepion Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Hepion Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

CASI Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

In the previous week, Hepion Pharmaceuticals had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for Hepion Pharmaceuticals and 0 mentions for CASI Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 0.67 beat CASI Pharmaceuticals' score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Hepion Pharmaceuticals	Positive

CASI Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CASI Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CASI Pharmaceuticals beats Hepion Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

GeoVax Labs has a beta of 3.73, suggesting that its stock price is 273% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

GeoVax Labs' return on equity of -743.64% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

GeoVax Labs has higher revenue and earnings than Hepion Pharmaceuticals. GeoVax Labs is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.01	-$21.47M	-$11.34	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

In the previous week, GeoVax Labs had 7 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 8 mentions for GeoVax Labs and 1 mentions for Hepion Pharmaceuticals. GeoVax Labs' average media sentiment score of 0.88 beat Hepion Pharmaceuticals' score of 0.67 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hepion Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GeoVax Labs currently has a consensus price target of $150.00, indicating a potential upside of 20,698.67%. Given GeoVax Labs' stronger consensus rating and higher possible upside, research analysts plainly believe GeoVax Labs is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

GeoVax Labs beats Hepion Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Decoy Therapeutics?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Decoy Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Decoy Therapeutics' return on equity of -395.42% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Decoy Therapeutics	N/A	-395.42%	-193.30%

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Decoy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 638.92%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Hepion Pharmaceuticals and Hepion Pharmaceuticals both had 1 articles in the media. Hepion Pharmaceuticals' average media sentiment score of 0.67 beat Decoy Therapeutics' score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hepion Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Decoy Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Decoy Therapeutics beats Hepion Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Hepion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HEPA vs. The Competition

Export

Metric	Hepion Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$686K	$11.73B	$6.95B	$12.87B
Dividend Yield	N/A	2.71%	2.59%	9.93%
P/E Ratio	-0.01	791.86	271.13	25.30
Price / Sales	N/A	971.87	658.25	106.23
Price / Cash	N/A	72.59	71.89	50.37
Price / Book	0.05	10.81	13.03	6.13
Net Income	-$48.93M	$2.79B	$3.46B	$342.95M
7 Day Performance	N/A	3.21%	3.41%	3.19%
1 Month Performance	N/A	-1.72%	-2.67%	-1.98%
1 Year Performance	N/A	193.26%	75.99%	21.11%

Hepion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HEPA Hepion Pharmaceuticals	N/A	$0.06 -14.2%	N/A	+49.3%	$686K	N/A	N/A	20	Gap Down
SNYR Synergy CHC	2.5088 of 5 stars	$0.17 +0.2%	$6.25 +3,559.3%	-95.6%	$2.58M	$30.38M	N/A	40	Positive News Gap Down
GRI GRI Bio	1.8541 of 5 stars	$1.45 +1.4%	$32.00 +2,106.9%	-95.6%	$2.57M	N/A	N/A	1	News Coverage Positive News Upcoming Earnings
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180
GOVX GeoVax Labs	2.4089 of 5 stars	$0.70 -3.9%	$150.00 +21,383.8%	-95.6%	$2.42M	$2.49M	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HEPA) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. SNYR, GRI, CASI, GOVX, and DCOY

How does Hepion Pharmaceuticals compare to Synergy CHC?

Summary

How does Hepion Pharmaceuticals compare to GRI Bio?

Summary

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Summary

How does Hepion Pharmaceuticals compare to GeoVax Labs?

Summary

How does Hepion Pharmaceuticals compare to Decoy Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. SNYR, GRI, CASI, GOVX, and DCOY

How does Hepion Pharmaceuticals compare to Synergy CHC?

Do analysts recommend HEPA or SNYR?

Do insiders & institutionals hold more shares of HEPA or SNYR?

Does the media refer more to HEPA or SNYR?

Which has more risk & volatility, HEPA or SNYR?

Which has higher valuation & earnings, HEPA or SNYR?

Is HEPA or SNYR more profitable?

Summary

How does Hepion Pharmaceuticals compare to GRI Bio?

Do institutionals and insiders have more ownership in HEPA or GRI?

Do analysts prefer HEPA or GRI?

Does the media favor HEPA or GRI?

Which has more risk & volatility, HEPA or GRI?

Is HEPA or GRI more profitable?

Which has stronger earnings & valuation, HEPA or GRI?

Summary

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Is CASI or HEPA more profitable?

Which has stronger earnings & valuation, CASI or HEPA?

Does the media refer more to CASI or HEPA?

Which has more volatility and risk, CASI or HEPA?

Do insiders and institutionals believe in CASI or HEPA?

Do analysts recommend CASI or HEPA?

Summary

How does Hepion Pharmaceuticals compare to GeoVax Labs?

Which has more risk and volatility, GOVX or HEPA?

Is GOVX or HEPA more profitable?

Which has preferable valuation & earnings, GOVX or HEPA?

Does the media prefer GOVX or HEPA?

Do insiders and institutionals hold more shares of GOVX or HEPA?

Do analysts recommend GOVX or HEPA?

Summary

How does Hepion Pharmaceuticals compare to Decoy Therapeutics?

Which has more volatility and risk, HEPA or DCOY?

Which has higher earnings and valuation, HEPA or DCOY?

Is HEPA or DCOY more profitable?

Do institutionals and insiders hold more shares of HEPA or DCOY?

Do analysts rate HEPA or DCOY?

Does the media favor HEPA or DCOY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools